ArticleESMO open2026
Impact of treatment discontinuation among patients with microsatellite instability or mismatch repair-deficient metastatic colorectal cancer treated with immune checkpoint inhibitors.
Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe optimal duration of immune checkpoint inhibitor (ICI) treatment in patients with metastatic colorectal cancer (mCRC) with microsatellite instability/mismatch repair deficiency (MSI/dMMR) remains undefined. PATIENTS AND
methodsWe retrospectively analyzed data of 84 patients with MSI/dMMR mCRC treated with ICIs at any line of therapy who discontinued treatment for any reason.
resultsAfter a median follow-up period of 48 months, 51% of patients stopped treatment due to disease progression and 49% discontinued for other reasons, including immune-related adverse events, clinical benefit, protocol completion (2 years), surgery, or pregnancy. Among patients who discontinued without progression, treatment cessation did not negatively impact progression-free survival or overall survival. Patients who achieved radiologic response and stopped without progression rarely relapsed. Liquid biopsy analysis using circulating tumor DNA (ctDNA) was available from 48 patients. Among those who stopped per protocol, nearly 80% had negative ctDNA at discontinuation, with only 7% of them progressing during follow-up. Conversely, among those patients who progressed, 78.3% had positive liquid biopsy results at treatment discontinuation, underscoring the complexity of molecular monitoring.
conclusionsThese findings support the safety of early ICI discontinuation (<2 years) in responding patients and suggest that ctDNA may aid in identifying optimal stopping points. However, due to the retrospective design and limited sampling, these results should be interpreted as hypothesis-generating. Prospective studies are required to define the precise role of ctDNA in guiding ICI duration in dMMR/MSI mCRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.